Innovating Women’s Reproductive Health and Pregnancy Therapeutics
ObsEva is a biopharmaceutical company innovating women’s reproductive health and pregnancy therapeutics from conception to birth.
Between the ages of 20 and 50, millions of women worldwide suffer from reproductive health conditions that affect their quality of life and their ability to conceive or may lead to complications during pregnancy. ObsEva aims to improve upon the current treatment landscape with the development of novel, oral medicines with potentially best-in-class safety and efficacy profiles.
Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with multiple development programs focused on treating endometriosis, uterine fibroids, and preterm labor.
ObsEva is supported by top-tier investors and a globally recognized board and is well-positioned to establish a leadership position in women’s reproductive therapeutics.
ObsEva is advancing a robust pipeline of novel, oral, late-stage compounds to treat women’s reproductive health conditions
from conception to birth.
Unique value proposition with dual blockbuster indications for OBE2109 and OBE001.
ADVANCED REPRODUCTIVE THERAPEUTICS PIPELINE
A robust growth strategy is important to a fast developing specialty biopharmaceutical company. Through strategic in-licensing and productive academic collaborations, ObsEva is building a meaningful clinical portfolio around multiple reproductive therapeutic assets that can address significant unmet medical needs for millions of women worldwide.
How to contact ObsEva ?» contact us